ReviewHematology/oncology clinics of North America2012
Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.
Review in Hematology/oncology clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Trial
- TruncatingbioRxiv : the preprint server for biology · 2026Article
- Novel germlineChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.Journal of clinical laboratory analysis · 2022Article
- Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.International journal of molecular sciences · 2022Review
- Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era.Journal of clinical medicine · 2021Article
- [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Review
- Recent insights regarding the molecular basis of myeloproliferative neoplasms.The Korean journal of internal medicine · 2020Review
- Analysis of genes encoding epigenetic regulators in myeloproliferative neoplasms: Coexistence of a novelMolecular and clinical oncology · 2019Article
- Disruption ofDisease models & mechanisms · 2019Article
- Epigenetics in Myeloproliferative Neoplasms.Journal of cellular and molecular medicine · 2017Review
- The NF1 somatic mutational landscape in sporadic human cancers.Human genomics · 2017Review
- Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Expert review of hematology · 2016Article
- Article
- Molecular genetics of myelofibrosis and its associated disease phenotypes.Translational medicine @ UniSa · 2014Article
- The new landscape of therapy for myelofibrosis.Current hematologic malignancy reports · 2013Review
- Genetics of myeloproliferative neoplasms.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Since the discovery of activating mutations in JAK2 in patients with myeloproliferative neoplasms (MPNs) in 2005, gene discovery efforts have identified additional disease alleles, which can predate or occur subsequent to acquisition of JAK2/MPL mutations. In 2009, somatic copy number loss and mutations in the genes TET2 and ASXL1 were identified in MPN patients. Genetic analysis of MPN patient cohorts with adequate sample size and clear clinical annotation are needed to understand the importance of these mutations on MPN phenotype, risk of transformation to leukemia, response to therapy, and influence on overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.